AllSci News
Ascletis reports positive phase II data for ASC30 depot formulation in obesity treatment
Hong Kong-based Ascletis Pharma Inc. announced topline results from a US Phase II study of ASC30, a small molecule GLP-1 receptor agonist formulated as a...
Wave Life Sciences' WVE-007 shows visceral fat reduction in Phase I obesity trial
Wave Life Sciences reported interim WVE-007 clinical data from the Phase I portion of its INLIGHT trial, showing that a single 240 mg dose of the...
Lundbeck's bocunebart meets primary endpoint in Phase IIb migraine prevention trial
Denmark-based H. Lundbeck A/S announced positive topline results from the intravenous dosing arm of its Phase IIb PROCEED trial evaluating bocunebart (Lu...
Diamyd Medical Secures Up to USD 125m in Equity Financing From US Specialist Investors
Stockholm-headquartered Diamyd Medical, a biotech company developing precision medicine therapies for type 1 diabetes, has entered into equity financing...
Elephas Biosciences Partners With University of Louisville to Study Immunotherapy Response in GI Cancers
Elephas Biosciences Corporation, a privately held Madison, Wisconsin-based company focused on live tissue immunotherapy response prediction, has entered...
Structure Therapeutics' aleniglipron achieves 16.3% weight loss in phase 2 obesity trial
Structure Therapeutics (NASDAQ: GPCR), a San Francisco-based clinical-stage biopharmaceutical company, reported topline data from its Phase 2 ACCESS II...
Clover Biopharmaceuticals' SCB-1019 shows positive Phase I RSV re-vaccination data in older adults
Clover Biopharmaceuticals (HKEX: 02197), a Shanghai-based biotechnology company, reported additional Phase I data for its RSV prefusion F protein vaccine...
Drug Farm's DF-003 Secured US FDA Orphan Drug Designation for ROSAH Syndrome
Drug Farm, a private biotechnology company with operations in Albany, New York, and Shanghai, announced that the U.S. Food and Drug Administration (FDA) has...
FDA Grants ENHERTU Priority Review for HER2-Positive Early Breast Cancer Post-Neoadjuvant Treatment
Daiichi Sankyo Co., Ltd. (TSE: 4568), headquartered in Tokyo, and AstraZeneca (LSE/STO/NYSE: AZN), headquartered in Cambridge, UK, announced that the U.S....
Sentynl Therapeutics licenses PRG S&T's oral progeria drug Progerinin for clinical development
Sentynl Therapeutics, a U.S.-based subsidiary of Zydus Lifesciences, has entered into a licensing agreement with South Korean rare disease company PRG S&T...
Kainova Therapeutics' DT-9081 shows early promise in Phase I advanced solid tumors trial
Montreal-based Kainova Therapeutics announced topline results from its Phase I EPRAD study of DT-9081, an oral EP4 receptor antagonist, in patients with...
Researchers report first in vivo CAR-T cell generation in multiple myeloma patients using ESO-T01 vector
Investigators in China report that a single intravenous infusion of ESO-T01, a nanobody-directed lentiviral vector, generated functional anti-BCMA CAR-T...
MiNK Therapeutics and C-Further collaborate on PRAME-targeted iNKT cell therapy for pediatric cancers
New York-based MiNK Therapeutics, Inc. (Nasdaq: INKT) and C-Further, a London-headquartered international pediatric oncology consortium enabled by Cancer...
Novomedix wins $2.98 million NCI contract to advance oral drug for pediatric solid tumors
Novomedix, a San Diego-based for-profit company, has received a $2.98 million SBIR Phase II contract from the National Cancer Institute to advance a...
Akeso's first-in-class trispecific antibody hits ILT2, ILT4, and CSF1R to dismantle myeloid immunosuppression in solid tumors
Akeso's trispecific antibody AK150, which simultaneously targets the immunosuppressive receptors ILT2, ILT4, and CSF1R, has received Investigational New...
The AllSci Brief
Systematic R&D and deal news. Daily.